Pulmatrix (PULM) Stock Price Down 14.4%

Pulmatrix Inc (NASDAQ:PULM) was down 14.4% on Monday . The company traded as low as $0.86 and last traded at $0.77. Approximately 14,193 shares changed hands during trading, a decline of 98% from the average daily volume of 699,788 shares. The stock had previously closed at $0.90.

A number of equities research analysts recently weighed in on PULM shares. HC Wainwright reaffirmed a “buy” rating on shares of Pulmatrix in a report on Monday, November 19th. ValuEngine raised shares of Pulmatrix from a “hold” rating to a “buy” rating in a report on Thursday, November 1st.

The firm has a market cap of $4.74 million, a price-to-earnings ratio of -0.08 and a beta of 1.72.

Pulmatrix (NASDAQ:PULM) last posted its quarterly earnings data on Wednesday, November 14th. The biotechnology company reported ($1.00) EPS for the quarter, beating the Zacks’ consensus estimate of ($1.40) by $0.40. As a group, sell-side analysts predict that Pulmatrix Inc will post -6.45 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece was published by Community Financial News and is the property of of Community Financial News. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.com-unik.info/2019/02/13/pulmatrix-pulm-stock-price-down-14-4.html.

About Pulmatrix (NASDAQ:PULM)

Pulmatrix, Inc, a clinical stage biopharmaceutical company, develops inhaled therapies to address serious pulmonary diseases using its inhaled Small Particles Easily Respirable and Emitted (iSPERSE) technology. Its proprietary product pipeline focuses on advancing treatments for serious lung diseases, including Pulmazole, an inhaled anti-fungal for patients with allergic bronchopulmonary aspergillosis; and PUR1800, kinase inhibitor for patients with obstructive lung diseases, including asthma and chronic obstructive pulmonary disease (COPD).

See Also: Index Funds

Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit